Free Trial
NASDAQ:DSGN

Design Therapeutics Q3 2023 Earnings Report

Design Therapeutics logo
$3.50 +0.12 (+3.55%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$3.51 +0.01 (+0.29%)
As of 04/17/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Design Therapeutics EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.42
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

Design Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Design Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, November 13, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

Design Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Thursday, May 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Design Therapeutics Earnings Headlines

Design Therapeutics appoints Chris Storgard as CMO
Claim Your FREE Protection Guide
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
Design Therapeutics price target raised to $5 from $4 at RBC Capital
See More Design Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Design Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Design Therapeutics and other key companies, straight to your email.

About Design Therapeutics

Design Therapeutics (NASDAQ:DSGN) a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

View Design Therapeutics Profile

More Earnings Resources from MarketBeat